A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

Phase 2 Completed NCT01387555

Condition	Hepatocellular Carcinoma, Liver Cancer, HCC
Phase	Phase 2
Sponsor	Jennerex Biotherapeutics
Status	Completed
Enrollment	129 participants
Interventions	JX-594 recombinant vaccina GM-CSF, Best Supportive Care
Start date	Oct 8, 2011
Completion date	Oct 1, 2013
Results posted	Jul 8, 2026

Summary

This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.

Survival

From randomization until death from any cause, assessed up to 21 months. · months

JX-594 + Best Supportive Care	4.2 months
Best Supportive Care	4.4 months

p-value	0.426
Hazard Ratio (HR)	1.19 (95% CI 0.78–1.80)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский